IBI is an innovative hi-tech Swiss biomedical company focused on research, development and production of medical devices for tissue engineering and regenerative medicine: substitutes, grafts, 3D matrixes and 2D scaffolds.
IBI believes that regenerative medicine and tissue engineering represent the future for health.
IBI has strong competencies and core skills in processing materials for biomedical applications, used to develop proprietary technologies to build its new and innovative products.
IBI pays extreme attention to safety and quality: IBI is ISO13485 certified.
Lorenzo Leoni was born in Lugano (Switzerland) in 1965, he obtained a Ph.D. in Biochemistry at the University of Lausanne and later became Assistant Professor of Medicine at the University California San Diego, in the departments of Immunology and Oncology.
He is a serial biotech entrepreneur, and has founded successful biotech companies in the United States (Salmedix) and in Switzerland (Telormedix). He has been COO of a now public Swiss biotech company and CEO of Telormedix until the end of 2009.
He is currently General Manager of the AGIRE Foundation, the Innovation Agency of the Ticino Canton and Managing Partner of AGIRE INVEST SA.
Giuseppe Perale was born in Venice (Italy) in 1978, he attained both his Master’s Degree and his PhD in Biomedical Engineering, in 2002 and 2006 respectively, at the Politecnico di Milano. Visiting Post Doc at the Imperial College London in 2007, visiting Researcher at the Karolinska Institutet in Stockholm in 2011 and at the IRF “Mario Negri” in 2012, he was Acting Professor of “Formulations Science” at the Politecnico di Milano until Spring 2013. Currently he is Full Professor of Industrial Bioengineering at the SUPSI Swiss University.
His studies are mainly focused on process engineering and physical chemistry applied to biomaterials for medical applications, particularly for tissue engineering and drug delivery systems. He’s author in over 100 international publications and 3 patent families.
Gianni Pertici was born in Pontedera (Pisa, Italy) in 1976, got his Master’s Degree in Chemical Engineering in 2002 at the University of Pisa and from 2005 to 2008 performed his PhD in Biomaterials at the Dept. of Chemistry of University of Pisa and at the Dental Dept. at King’s College of London.
His studies were focused on processing engineering and material properties especially for the biomedical field, but in recent years he acquired good knowledge also in the biological field, particularly in cell culture methods. In 2008 he moved to Switzerland where he became R&D director of Swiss Stem Cell Bank, in the same year he founded IBI. He is author in more than 30 publications, 2 books and single inventor of 2 patents. Currently he is also Researcher at the SUPSI Swiss University.
Michele Müller was born in 1956 in Montevarchi (Arezzo, Italy) but grew in Switzerland in the city of Lugano. He got his Master’s Degree in Natural Science in 1979 at the Swiss Federal Institute of Technology (ETH), where in 1983 he got also his PhD in Biochemistry.
He has a long experience as a Researcher in the field of biochemistry and proteomics, achieved from 1984 to 1995 at the universities of Bern (CH) and Nice (Fr). In 1995 he started his industrial career as senior R&D in Cerbios-Pharma S/A. In 1998 he left to establish Micro-Sphere S/A, where he’s now General Manager.
Industrie Biomediche Insubri SA is a Swiss Company established under the Swiss Federal Law.
Via Cantonale 67
CH-6805 Mezzovico-Vira (Ticino)
VAT code: CHE-112.388.119 IVA
Registration number at the Chamber of Commerce of the Canton Ticino: CH-514.3.029.225-5
Swiss Company Register Identification Number: CHE-112.388.119
To contact us click here!
IBI is established as a privately owned company, under the Swiss Federal Laws.
IBI establishes in Mezzovico (Ticino, Switzerland) its Headquarter and Laboratories; IBI establishes its production at Micro-Sphere S.A., in a cGMP certified environment.
IBI is among partners of the Italian/Swiss InterReg project “Clu.B.”, financed under the patronage of the European Commission by the Italian Regione Lombardia, the Swiss Federal Government and the Ticino Economic Development Office.
IBI starts selling SmartBone for lab use in cell therapies development for bone regeneration.
Phoenix|x-ray (a GE company) runs innovative microCT scans on SmartBone.
IBI welcomes Gianfranco Colomba as its C.E.O.
IBI opens its European Branch.
IBI obtains the approval for clinical studies on SmartBone.
Agire Invest SA, the Development Agency of the Ministry of Economics of the Canton Ticino, joins IBI shareholders entering into equity as an Investor.
IBI secures a second investment round from Fondazione “Filippo Serpero”.
IBI obtains ISO 13485 and ISO 9001 certifications and its SmartBone obtains the CE mark for human use!
The Compagnie Financiere St. Exupéry SA has become one of IBI’s shareholders and has expressed Dr. Claudio Girardi as director and vice-president.